ChemPartnerPharmaTech to Speak at ACCESS CHINA Boston Forum

May 19th, 2023 (Shanghai) — We are glad to announce that Jiguo Zhang, the CEO of ChemPartner PharmaTech, has been invited as a keynote speaker at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.

About ChemPartner

Chempartner is an innovative enterprise (CRO+CDMO) that adheres to the concept of “science first, technology first” and provides integrated pharmaceutical research and development and production services. After years of development,Chempartner has accumulated cutting-edge, diverse, and comprehensive technology, formed a top scientific research talent team, equipped with advanced scientific research facilities, animal experimental facilities, and pharmaceutical intermediate production facilities. It has established research and development and production bases in Zhangjiang/Jinqiao/Lingang, Jiangsu Qidong, Sichuan Chengdu, and San Francisco, USA, and can provide global pharmaceutical enterprises with Biotechnology companies and research institutions provide full lifecycle services for new drugs, covering chemical drug research and development, as well as biopharmaceuticals from early discovery to commercial production.Nowadays,Chempartner has established strategic partnerships with over 150 top global biopharmaceutical research institutions and enterprises; We have provided services to over 3000 global pharmaceutical and biopharmaceutical technology companies, covering the top 20 multinational pharmaceutical companies globally.

公司简介

睿智医药是一家秉承 “ 科学为本，技术为先”理念、提供医药研发与生产一体化服务的创新型企业（CRO+CDMO）。经过多年的发展，睿智医药拥有前沿、多元且全面的技术积累，组建顶尖的科研人才队伍，配置先进的科研设施、动物实验设施以及医药中间体生产设施，在上海张江/金桥/临港、江苏启东、四川成都和美国旧金山布局研发和生产基地，能够为全球制药企业、生物技术公司以及科研院校提供涵盖化学药研发以及生物药从早期发现到商业化生产的新药全生命周期服务。

如今，睿智医药已经与150多家全球顶尖生物医药研究机构及企业建立战略合作；累计为超过3000家全球制药企业和生物医药技术公司提供服务，基本涵盖了全球排名前20的跨国大药企。

About the speaker

Mr. Jeffrey Zhang, CEO of ChemPartner PharmaTech Co., Ltd. Previously, he served as a senior executive at Pfizer, J&J, WuXi, etc. accumulating rich experiences in strategic planning, business development, and business management. Mr. Jeffrey Zhang graduated with honors from Peking University. He is also member of the China Vaccine Industry Association, and honorary president of the China Health Business Development Association (CHBD).

专家简介

张继国先生担任睿智医药CEO，此前曾在辉瑞、药明等公司担任高管，在战略规划、业务发展、公司管理等方面积累了丰富经验。张继国先生以优异的成绩毕业于北京大学医学部以及北京大学国家发展研究院，毕业后曾留校任教。张继国先生也是虹博基因的联合创始人兼CEO，同时也是中国疫苗行业协会委员，中国大健康业务发展协会（CHBD）荣誉会长。

About ACCESS CHINA Boston Forum

“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.

Conference Name: ACCESS CHINA – Boston Forum @BIO

Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)

Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception

Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows

Participants: Pharma/Biotech senior management and BDs, investors.

View more information at https://biotochina.org/

关于药通中国-波士顿论坛

“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。

大会名称：药通中国-波士顿论坛@BIO

大会日期：2023.6.4（周日，波士顿） 2023.6.13-15（线上）

大会内容：主题演讲、圆桌讨论、海内外优质项目路演、睿智医药-药通中国招待晚宴

大会规模：预计线上1000参会者；线下150参会者; 100场公司路演